CA3037059A1 - Compositions and methods for treating alzheimer's disease and parkinson's disease - Google Patents
Compositions and methods for treating alzheimer's disease and parkinson's disease Download PDFInfo
- Publication number
- CA3037059A1 CA3037059A1 CA3037059A CA3037059A CA3037059A1 CA 3037059 A1 CA3037059 A1 CA 3037059A1 CA 3037059 A CA3037059 A CA 3037059A CA 3037059 A CA3037059 A CA 3037059A CA 3037059 A1 CA3037059 A1 CA 3037059A1
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- syn120
- day
- another embodiment
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402357P | 2016-09-30 | 2016-09-30 | |
| US62/402,357 | 2016-09-30 | ||
| PCT/US2017/054473 WO2018064559A1 (en) | 2016-09-30 | 2017-09-29 | Compositions and methods for treating alzheimer's disease and parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3037059A1 true CA3037059A1 (en) | 2018-04-05 |
Family
ID=61756894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037059A Abandoned CA3037059A1 (en) | 2016-09-30 | 2017-09-29 | Compositions and methods for treating alzheimer's disease and parkinson's disease |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10314798B2 (enExample) |
| EP (1) | EP3518914A4 (enExample) |
| JP (1) | JP2019529502A (enExample) |
| AR (1) | AR109760A1 (enExample) |
| AU (2) | AU2017337053B2 (enExample) |
| CA (1) | CA3037059A1 (enExample) |
| IL (1) | IL265656A (enExample) |
| MX (2) | MX387961B (enExample) |
| TW (1) | TWI753952B (enExample) |
| WO (1) | WO2018064559A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018064559A1 (en) | 2016-09-30 | 2018-04-05 | Biotie Therapies, Inc. | Compositions and methods for treating alzheimer's disease and parkinson's disease |
| EP4054537B1 (en) * | 2019-11-04 | 2023-06-07 | Cinclus Pharma Holding AB (publ) | Oral formulation of x842 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2368083A1 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| CN101119965B (zh) * | 2004-12-21 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 萘满和茚满衍生物及其用途 |
| MX2008015843A (es) * | 2006-06-20 | 2009-01-09 | Hoffmann La Roche | Derivados de tetralina e indano y usos de los mismos. |
| FR2974102B1 (fr) * | 2011-04-13 | 2014-08-22 | Rhodia Operations | Composition polyamide stabilisee |
| WO2015173133A1 (en) * | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| WO2018064559A1 (en) | 2016-09-30 | 2018-04-05 | Biotie Therapies, Inc. | Compositions and methods for treating alzheimer's disease and parkinson's disease |
-
2017
- 2017-09-29 WO PCT/US2017/054473 patent/WO2018064559A1/en not_active Ceased
- 2017-09-29 US US15/720,947 patent/US10314798B2/en not_active Expired - Fee Related
- 2017-09-29 AR ARP170102714A patent/AR109760A1/es unknown
- 2017-09-29 EP EP17857545.2A patent/EP3518914A4/en not_active Withdrawn
- 2017-09-29 JP JP2019517827A patent/JP2019529502A/ja active Pending
- 2017-09-29 CA CA3037059A patent/CA3037059A1/en not_active Abandoned
- 2017-09-29 TW TW106133810A patent/TWI753952B/zh not_active IP Right Cessation
- 2017-09-29 MX MX2019003720A patent/MX387961B/es unknown
- 2017-09-29 AU AU2017337053A patent/AU2017337053B2/en not_active Ceased
-
2019
- 2019-01-16 US US16/249,290 patent/US10973784B2/en not_active Expired - Fee Related
- 2019-03-27 IL IL265656A patent/IL265656A/en unknown
- 2019-03-29 MX MX2021014093A patent/MX2021014093A/es unknown
-
2021
- 2021-03-01 US US17/188,413 patent/US20210177783A1/en not_active Abandoned
- 2021-12-01 AU AU2021277698A patent/AU2021277698A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021277698A1 (en) | 2021-12-23 |
| MX2019003720A (es) | 2019-09-19 |
| MX2021014093A (es) | 2021-12-10 |
| US20180092868A1 (en) | 2018-04-05 |
| AU2017337053A1 (en) | 2019-04-04 |
| AU2017337053B2 (en) | 2021-09-02 |
| EP3518914A4 (en) | 2020-06-10 |
| TWI753952B (zh) | 2022-02-01 |
| US10973784B2 (en) | 2021-04-13 |
| US20210177783A1 (en) | 2021-06-17 |
| US20190142771A1 (en) | 2019-05-16 |
| WO2018064559A1 (en) | 2018-04-05 |
| MX387961B (es) | 2025-03-19 |
| US10314798B2 (en) | 2019-06-11 |
| AR109760A1 (es) | 2019-01-23 |
| TW201813638A (zh) | 2018-04-16 |
| JP2019529502A (ja) | 2019-10-17 |
| IL265656A (en) | 2019-05-30 |
| EP3518914A1 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4084309B2 (ja) | 単一の結晶形を含有する固形製剤 | |
| EP3501506B1 (en) | Pharmaceutical tablet composition comprising brexpiprazole | |
| KR101682963B1 (ko) | 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제 | |
| EP3749286B1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| CN112739334B (zh) | 结晶丙二酸肾上腺素盐 | |
| KR20100015582A (ko) | 4,5-에폭시모르피난 유도체를 함유하는 안정한 고형 제제 | |
| IL293879A (en) | Compositions of bile acids and phenylbutyrate compounds | |
| CA2936108A1 (en) | Novel compositions | |
| AU2021277698A1 (en) | Compositions and methods for treating Alzheimer's disease and Parkinson's disease | |
| JP2025169294A (ja) | カルバメート化合物を含む経口用医薬組成物及びその製造方法 | |
| WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| WO2010041277A2 (en) | Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates | |
| WO2008071966A2 (en) | Pharmaceutical composition of zolpidem | |
| JP7336528B2 (ja) | ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物 | |
| EP1781292B1 (en) | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one | |
| EP4233849A1 (en) | Pharmaceutical composition comprising pomalidomide | |
| EA033685B1 (ru) | Фармацевтические лекарственные формы | |
| JP2011153135A (ja) | タルチレリン製剤およびタルチレリン製剤の溶出性維持方法 | |
| RU2410097C2 (ru) | Лекарственная форма триметазидина модифицированного высвобождения и способ ее получения (варианты) | |
| HK40072206A (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
| WO2007030589A2 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan | |
| EA052633B1 (ru) | Фармацевтическая композиция, содержащая помалидомид | |
| HK40045152A (en) | Crystalline epinephrine malonate salt | |
| HK1155364A (en) | Eprosartan compositions | |
| HK1164742A1 (en) | Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240110 |